Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Ne…

August 5, 2010 By Bio-Medicine.Org

WALTHAM, Mass., Aug. 5 /PRNewswire/ — Decision Resources,
one of the world’s leading research and advisory firms for
pharmaceutical and healthcare issues, finds that, in first- and
second-line treatment of Clostridium difficile
infection (CDI), nearly 70 percent of surveyed infectious
disease specialists and internists will use Optimer’s fidaxomicin
and nearly half will use Medarex/Merck’s CDA1 and CDB1, one year
after the launch of these agents. The lower recurrent/relapse rate
associated with fidaxomicin and CDA1/CDB1 is the most influential
attribute surveyed clinicians cite in their decisions to prescribe
these emerging agents for CDI.

The new Physician & Payer Forum report entitled Hospital
Anti-Infectives: Insights on the Uptake and Formulary Inclusion of
Emerging Antibiotics and Antifungals—A Survey of Infectious
Disease Specialists, Internists and P&T Committee Members

finds that fidaxomicin and, to a higher degree, CDA1/CDB1, will
also see robust uptake by surveyed clinicians for the treatment of
recurrent CDI. The report also finds that approximately two-thirds
of pharmacy and therapeutics committee (P&T) members expect to
include fidaxomicin and CDA1/CDB1 on their hospital’s
formulary.

Fidaxomicin and CDA1/CDB1 would provide much needed options for
the treatment of CDI as the only currently available agents in this
indication are Pfizer’s metronidazole (generically available) and
ViroPharma’s Vancocin. According to the report, unmet need
for novel anti-infectives is shifting away from
methicillin-resistant Staphylococcus aureus (MRSA) to CDI
and gram-negative infections.

“In addition to MRSA, infectious disease specialists report a
rise in CDI and gram-negative infections,” said Decision Resources
Therap

‘/>”/>

SOURCE

Related Articles Read More >

A photo of nitinol, a nickel-titanium alloy used for medical devices such as stents, heart valves, catheters and orthopedics.
What is nitinol and where is it used?
An image of Abbott's Infinity deep brain stimulation (DBS) implants and leads.
How Abbott developed the first-of-its-kind Infinity DBS system
Axoft Fleuron brain-computer interface BCI probe
Axoft makes Fleuron BCI material available for purchase, inks license deal with Stanford
An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]
The top nitinol cardiac medtech news of 2025 (so far)
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe